Loading, Please Wait...
WEST LAFAYETTE, Ind., May 21, 2019 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) is pleased to announce the launch of the Company’s redesigned Raturn™, a movement response system that is designed for tether-based applications in awake animals.
Used as an alternative to liquid swivels or commutators, the Raturn™ interactively responds to animal movement to keep wires, tubing, fluid lines, optic and electrical cables from twisting. BASi’s Raturn™ systems are used in academic research, pharmaceutical laboratories, and CROs for a wide range of applications, including in vivo microdialysis, blood collection, optogenetics, ECG studies, blood pressure, and activity monitoring. Since the original launch in the mid-90s, the Raturn™ has helped researchers produce hundreds of publications for a range of applications.
“The objective of the Raturn™ is to help researchers obtain better data by simplifying sample collection while minimizing stress to the animal,” said Lauren Elolf, PhD, BASi’s Products Business Development Manager. “It’s a great product, but we knew we could make it even better. The newly released version of the Raturn™ offers design improvements and user-friendly configurations. Even more importantly, the new system is more affordable, so a greater number of researchers can take advantage of the benefits it has to offer,” concluded Dr. Elolf.
Demonstrating cross-functional use and high-throughput capabilities, Raturns™ are available as stand-alone systems, part of the Culex Automated in Vivo Sampling System, or customizable configurations as single or multiple units. The Raturn™ is compatible with BASi’s current line of cage options and integrates with a number of existing products, further strengthening the Company’s portfolio to generate better data while enhancing animal welfare—all at a reasonable price.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. BASi’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit www.BASinc.com for more information about BASi.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, and various market and operating risks detailed in the company's filings with the U.S. Securities and Exchange Commission.
Jill C. Blumhoff
Chief Financial Officer
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/034f438e-4b18-4445-b876-4fa2c49aa10b